The 60-second version of Albert David Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
Nothing stands out as clearly improving on the years of data available.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹340 Cr | ₹360 Cr | ₹343 Cr | ₹329 Cr | -1.1% |
| EBITDA | ₹56 Cr | ₹58 Cr | ₹13 Cr | ₹16 Cr | -34.0% |
| EBITDA Margin | 16.4% | 16.1% | 3.9% | 4.9% | — |
| PAT (Net Profit) | ₹36 Cr | ₹75 Cr | ₹17 Cr | -₹1 Cr | — |
| EPS | ₹63.39 | ₹132.15 | ₹30.14 | ₹-2.62 | — |
| ROE | 11.6% | 19.7% | 4.4% | -0.4% | — |
| ROCE | 15.7% | 24.4% | 6.3% | 0.8% | — |
| Total Debt | ₹5 Cr | ₹3 Cr | ₹12 Cr | ₹30 Cr | +77.2% |
| Free Cash Flow | ₹5 Cr | ₹35 Cr | -₹43 Cr | -₹37 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
Poor scores on business quality without a price low enough to compensate. There is no obvious argument for owning this over a stronger company at a similar valuation. 5 high-severity red flags sit above this conclusion and should be read first.